Innoviva, Inc.
INVAHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframePart of the healthcare sector, Innoviva, Inc. (INVA) is listed under Biotechnology. At a $1.49B market cap, Innoviva, Inc. ranks as a small-cap company within healthcare. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI.
Market Cap
$1.49B
Beta
0.38
P/E (TTM)
4.92
P/E (Fwd)
9.35
EPS (TTM)
$4.20
EPS (Fwd)
$2.21
ROE
36.7%
ROA
7.0%
Cash
$579.1M
Total Debt
$331.2M
Free CF
$110.3M
52W Change
16.7%
Annual Financials
Cash vs Debt
Where INVA stands vs its 150-day and 200-day moving averages
As of the October 12, 2026 close, INVA finished 3.68% below its 150-day moving average ($22.02) and 2.66% below its 200-day moving average ($21.79). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is INVA overbought or oversold?
At the October 12, 2026 close, INVA's RSI(14) was 52.2, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $579.1M in cash and $331.2M in debt, INVA maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow comes in at $110.3M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 36.7% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 7.0% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $331.3M (2022) to $411.3M (2025), reflecting a 24% increase over the period.
With a beta below 0.7, Innoviva, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing INVA.